Insmed Incorporated Growth, Revenue, Number of Employees and Funding
Navigation
Overview
Estimated Revenue & Financials
- Insmed Incorporated's estimated revenue is currently $97.3M per year.
- Insmed Incorporated received $437.3M in venture funding in January 2018.
- Insmed Incorporated's estimated revenue per employee is $230998
Employee Data
- Insmed Incorporated has 421 Employees.
- Insmed Incorporated grew their employee count by 11% last year.
- Insmed Incorporated currently has 22 job openings.
What Is Insmed Incorporated?
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company is dedicated to developing and bringing to market therapies that make a real difference in patients lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. Headquartered in Bridgewater, NJ, we are a rapidly growing company with offices in seven countries.
keywords:Biotechnology,Healthcare,Pharmaceuticals421
Number of Employees
$97.3M
Revenue (est)
22
Current Jobs
11%
Employee Growth %
N/A
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Similar Companies
| Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
| $75.8M | 528 | 3% | ||
| $29.9M | 242 | 13% | ||
| $75.8M | 528 | 3% | ||
| $29.9M | 242 | 13% | ||
| $29.3M | 202 | -32% | ||
| $21.5M | 181 | 23% | ||
| $29.3M | 202 | -32% | ||
| $21.5M | 181 | 23% | ||
| N/A | 0 | N/A | ||
| N/A | 0 | N/A |
Insmed Incorporated News
Insmed Incorporated (NASDAQ:INSM) traded under umbrella of Healthcare sector, apart from individual factors many macro and micro factors
As Biotechnology businesses, Ardelyx Inc. (NASDAQ:ARDX) and Insmed Incorporated (NASDAQ:INSM), are affected by contrast.
Insmed Incorporated (NASDAQ:INSM) Director Alfred Altomari sold 5,500 shares of the stock in a transaction that occurred on Tuesday,
Insmed Incorporated Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-07-14 | $12.0M | Private Placement | Wells Fargo Securities | Article |
| 2005-03-16 | $35.0M | Undisclosed | Multiple | Article |
| 2007-05-07 | $18.2M | Undisclosed | CE Unterberg Towbin | Article |
| 2012-10-01 | $26.0M | Undisclosed | Article | |
| 2013-07-18 | $62.4M | Undisclosed | Leerink Swann LLC | Article |
| 2014-08-13 | $80.0M | Undisclosed | Article | |
| 2015-04-01 | $194.0M | Undisclosed | Article | |
| 2015-04-07 | $223.0M | Undisclosed | Citigroup | Article |
| 2017-09-08 | $402.5M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2018-01-24 | $300.0M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2018-01-25 | $437.3M | Undisclosed | Goldman Sachs & Co. LLC | Article |
Insmed Incorporated Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2002-01-04 | Frederick Dunn | VP Clinical Development | Article |
| 2002-08-20 | Lewis Stuart | VP Commercial Dev | Article |
| 2002-09-10 | Mary Callan | VP Corporate Development | Article |
| 2003-06-20 | Ronald D. Gunn | EVP | Article |
| 2008-07-29 | Jim Miller | VP Process Development | Article |
| 2009-06-16 | Melvin Sharoky | Chairman | Article |
| 2010-03-23 | Nicholas A. LaBella | Chief Scientific Officer | Article |
| 2012-05-17 | Donald J. Hayden | Chairman | Article |
| 2012-09-12 | Will Lewis | President/CEO | Article |
| 2012-11-08 | Andrew Drechsler | Chief Financial Officer | Article |
| 2013-04-02 | Matthew Pauls | Chief Commercial Officer | Article |
| 2013-07-30 | Christine A. Pellizzari | General Counsel/Corporate Secretary | Article |
| 2015-03-24 | Eugene Sullivan | Chief Medical/Scientific Officer | Article |
| 2016-09-28 | Roger Adsett | Chief Commercial Officer | Article |
| 2019-03-28 | John Goll | Chief Accounting Officer | Article |
Insmed Incorporated Acquisitions
| Date | Company Name | Amount | Notes | Reference |
|---|---|---|---|---|
| 2009-02-16 | Article |